Description
NSE announces trading of rights entitlements for QMS Medical Allied Services Limited starting September 12, 2025.
Summary
NSE announces the commencement of trading in Rights Entitlements (REs) for QMS Medical Allied Services Limited on the SME EMERGE platform. Trading will begin on September 12, 2025, with specific trading periods for renunciation and mandatory disclosure requirements for trading members.
Key Points
- Rights Entitlements trading for QMS Medical Allied Services Limited (Symbol: QMSMEDI-RE)
- Trading commences on SME EMERGE platform from September 12, 2025
- Total 1,486,927 Rights Entitlements available
- Market lot size of 83 units
- Compulsory demat trading in Trade to Trade segment
- ISIN: INE0FMW20018
Regulatory Changes
Implementation under Regulation 3.1.1 and 2.5.5 of NSE Capital Market Trading Regulations Part A for securities admission and lot size specifications.
Compliance Requirements
- Trading members must inform clients about RE trading commencement and ISIN details
- Members must clarify that REs are not ordinary shares of the company
- Mandatory disclaimer in contract notes explaining RE purchase rights and consequences
- Members must inform clients about application requirements and renunciation options
- Warning about lapse and extinguishment of unused REs after Issue Closing Date
Important Dates
- Trading commencement: September 12, 2025
- Renunciation trading period: September 12-17, 2025
- Suspension date: September 18, 2025
- Circular effective date: September 12, 2025
Impact Assessment
Medium impact limited to QMS Medical Allied Services Limited shareholders and potential investors. The rights issue provides existing shareholders opportunity to subscribe to new shares or trade their entitlements. Mandatory disclosures ensure investor awareness of rights and obligations.
Impact Justification
Specific to QMS Medical rights issue trading with defined trading period